Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma
NCT03964298 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2025-08-11
Summary
Study of the activity of PD-1 inhibitors in metastatic uveal melanoma
Conditions
Sponsors & Collaborators
-
Institut Curie
lead OTHER
Principal Investigators
-
Manuel Rodrigues, MD · Institut Curie
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-11-30
- Primary Completion
- 2019-11-30
- Completion
- 2020-12-31
Countries
- France
Study Locations
More Related Trials
-
Precision Radiation of Immune Checkpoint Therapy Resistant Melanoma Metastases
NCT04793737 ·Status: RECRUITING ·Phase: NA
-
Immune Profiles Evolution Under Immunotherapy for Melanoma
NCT04576429 ·Status: RECRUITING ·Phase: NA
-
Understanding and Anticipating Therapeutic Response And Immuno-meDIated Adverse Events in Anti-cancer Immune-checkpoint Inhibition: a Tissue Biopsy Based imaGing Study
NCT05921123 ·Status: RECRUITING
-
Effectiveness, Safety and Use of Nivolumab Administered During the French Temporary Authorization for Use in Patients With Advanced Melanoma
NCT03504696 ·Status: COMPLETED
-
Optimization of the Patient Care Pathway in Immuno-oncology
NCT03329755 ·Status: COMPLETED ·Phase: NA
-
Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint Inhibitors
NCT05649683 ·Status: RECRUITING ·Phase: NA
-
Definition of an Immune Signature Predictive of Anti-PD1 (Programmed Death-1) Antibody in the Treatment of Advanced Melanoma
NCT02938728 ·Status: UNKNOWN
-
Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma
NCT01557114 ·Status: TERMINATED ·Phase: PHASE1
-
Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma
NCT03225365 ·Status: COMPLETED ·Phase: NA
-
Study of First-line Treatment Patterns and Clinical Outcomes in Patients With Advanced Melanoma in the United Kingdom
NCT03448497 ·Status: COMPLETED
-
Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System Metastasis
NCT05510466 ·Status: UNKNOWN
-
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
NCT05907954 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Melphalan Chemoreduction for Ocular Melanoma
NCT05893654 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1/PHASE2
-
Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma
NCT03313206 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients
NCT00849875 ·Status: TERMINATED ·Phase: PHASE2
-
Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma
NCT02275416 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma
NCT02843386 ·Status: COMPLETED ·Phase: PHASE3
-
Pruritus and Melanoma and Cutaneous Carcinomas Treated With Immunotherapy
NCT04365244 ·Status: COMPLETED
-
Anti PD-1 Plus Postbiotic Versus Anti PD-1 Alone in Locally Advanced or Metastatic, Treatment naïve, Cutaneous Melanoma Study
NCT07050940 ·Status: RECRUITING ·Phase: NA
-
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
NCT05987332 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma
NCT03356470 ·Status: COMPLETED
-
An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas
NCT05928962 ·Status: UNKNOWN ·Phase: PHASE1
-
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
NCT01511913 ·Status: COMPLETED
-
A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
NCT03417739 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151)
NCT02821000 ·Status: COMPLETED ·Phase: PHASE1